← All Researchers
Thomas Witzig
Professor of Medicine
Mayo Clinic · Rochester, United States
About
Longtime Mayo Clinic lymphoma and myeloma investigator with 400+ publications. Research on PI3K pathway inhibition and DNA damage response in MCL.
Specialties
PI3K inhibitorsDNA damage responseNovel agents
Key Trials
PI3K pathway inhibitor studies in MCL
Publications (3)
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.
British journal of haematology · Mar 10, 2026
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma.
The Journal of clinical investigation · Sep 2, 2025
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024